https://patelpatriot.substack.com/p/devolution-part-9
Devolution - The Military
Chain of command allows for Devolution.
Combatant Commands and Combatant Commanders report directly to SecDef who reports to the Military.
If Devolution was put in place due to evidence of a foreign attack on our critical infrastructure then Combatant Commanders would be the only ones to know until the reveal.
https://covid19criticalcare.com/ivermectin-in-covid-19/
Ivermectin in COVID-19
These pages contain the scientific rationale that justifies the use of ivermectin in COVID-19.
We regard ivermectin as a core medication in the prevention and treatment of COVID-19. For comprehensive information on ivermectin please refer to our Review of the Emerging Evidence Supporting the Use of Ivermectin in the Prophylaxis and Treatment of COVID-19 and the included references.
For questions about the safety of this medicine, you can read the expert review of over 350 articles on the medical safety profile of ivermectin that was conducted by a toxicologist for Medincell, which reported that “No safety concern was anticipated that would prevent health authorities from assessing the use of Ivermectin against COVID-19.” The review is available at www.medincell.com/ivermectin
-snip-
Ivermectin is a well-known, FDA-approved anti-parasite drug that has been used successfully for more than four decades to treat onchocerciasis “river blindness” and other parasitic diseases. It is one of the safest drugs known. It is on the WHO’s list of essential medicines, has been given 3.7 billion times around the globe, and has won the Nobel prize for its global and historic impacts in eradicating endemic parasitic infections in many parts of the world. Our medical discovery of a rapidly growing published medical evidence base, demonstrating ivermectin’s unique and highly potent ability to inhibit SARS-CoV-2 replication and to suppress inflammation, prompted our team to use ivermectin for prevention and treatment in all stages of COVID-19. Ivermectin is not yet FDA-approved for the treatment of COVID-19, but on Jan 14, 2021, the NIH changed their recommendation for the use of ivermectin in COVID-19 from “against” to “neutral”. (see our press release).
In March 2020 we created our life-saving MATH+ Hospital Treatment Protocol for COVID-19, which is intended for hospitalized patients. In October 2020 we developed the I-MASK+ Prophylaxis & Early Outpatient Treatment Protocol for COVID-19, which is designed for use as a prophylaxis and in early outpatient treatment, for those who test positive for COVID-19. The protocols complement each other, and both are physiologic-based combination treatment regimens developed by leaders in critical care medicine. All the component medicines are FDA-approved, inexpensive, readily available and have been used for decades with well-established safety profiles. Both protocols are available in several languages.